TrialInternational journal of cancer2010

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.

Markus M Heiss et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.